5:31 PM
 | 
Jan 16, 2013
 |  BC Extra  |  Company News

Hyperion gains on Ravicti update

Hyperion Therapeutics Inc. (NASDAQ:HPTX) said FDA told the company to expect a delay on a decision for an NDA for Ravicti glycerol phenylbutyrate because it is...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >